Madrigal Pharmaceuticals Inc (MDGL) — Titan Protect Analysis

MDGL

Madrigal Pharmaceuticals Inc

Healthcare · ·

$486.98

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$10.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

37.46

Based on estimated future earnings — lower means cheaper

Rev Growth

+126.8%

Year-over-year revenue change

Profit Margin

-27.3%

How much profit the company keeps from each dollar of revenue

ROE

-49.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$649.50

+33% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 14 analysts covering this stock

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

https://www.madrigalpharma.com

Country: United States Employees: 915 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.957

Good returns relative to risk taken

Kelly Fraction

0.0771

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.452

Returns exceed worst-case losses — strong risk profile

Annual Return

44.8%

Historical annualised return based on price data

Max Drawdown

-30.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-1.05

Very low correlation to market moves

52W High

$615.00

21% below the year high

52W Low

$271.96

79% above the year low

Avg Volume

318,128

Average daily shares traded — higher means easier to buy and sell

Short Ratio

14.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-13.50

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

63.91

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

93.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-29.8%

Profit from core operations before interest and tax

Free Cash Flow

$-156,403,504

Negative — the business is spending more than it generates

Revenue (TTM)

$1.1B

Total revenue over the last 12 months

Net Income

$-309,436,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$964.00

Target Median

$649.50

Target Low

$550.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go